Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for the stock over the next six months [11]. Core Insights - The company reported a revenue of 3.056 billion yuan for 2025, representing a year-on-year growth of 43.9%, with commercial sales revenue increasing by 51.5% [2][3]. - The inclusion of two innovative dual-antibody drugs, Cardunili and Ivorosi, in the national medical insurance directory has significantly boosted sales [2][3]. - The company has expanded its sales team to approximately 1,300 personnel, focusing on oncology and specialty drugs [3]. - Clinical data for core products continues to validate their global competitiveness, with Ivorosi achieving significant results in lung cancer treatment [3]. - The company is advancing its "IO2.0 + ADC2.0" strategy, with new products in the autoimmune metabolism field and ongoing clinical trials for next-generation ADC drugs [4]. Financial Summary - The company expects revenues of 5.161 billion yuan, 7.106 billion yuan, and 8.752 billion yuan for 2026, 2027, and 2028, respectively, with net profits projected at 244 million yuan, 1.111 billion yuan, and 1.569 billion yuan [4][6]. - The EBITDA loss for 2025 was 192 million yuan, a reduction from 241 million yuan in the previous year [2][3]. - The company’s gross margin is expected to improve, reaching 82.0% by 2028 [12].